Visualizing the invisible: The effect of asymptomatic transmission on the outbreak dynamics of COVID-19

[1]  J. Ioannidis,et al.  COVID-19 antibody seroprevalence in Santa Clara County, California , 2021, International journal of epidemiology.

[2]  K. Iwata,et al.  Estimation of seroprevalence of novel coronavirus disease (COVID-19) using preserved serum at an outpatient setting in Kobe, Japan: A cross-sectional study , 2020, Clinical Epidemiology and Global Health.

[3]  Sanyi Tang,et al.  Lessons drawn from China and South Korea for managing COVID-19 epidemic: Insights from a comparative modeling study , 2020, ISA Transactions.

[4]  P. Rahman,et al.  Is it safe to lift COVID-19 travel bans? The Newfoundland story , 2020, Computational mechanics.

[5]  Ellen Kuhl.  Data-driven modeling of COVID-19—Lessons learned , 2020, Extreme Mechanics Letters.

[6]  Tae Hyong Kim,et al.  Clinical Course and Molecular Viral Shedding Among Asymptomatic and Symptomatic Patients With SARS-CoV-2 Infection in a Community Treatment Center in the Republic of Korea. , 2020, JAMA internal medicine.

[7]  T. Zohdi.  An agent-based computational framework for simulation of global pandemic and social response on planet X , 2020, Computational Mechanics.

[8]  J. Oden,et al.  Bayesian-based predictions of COVID-19 evolution in Texas using multispecies mixture-theoretic continuum models , 2020, Computational Mechanics.

[9]  M. Peirlinck,et al.  The reproduction number of COVID-19 and its correlation with public health interventions , 2020, Computational mechanics.

[10]  C. Reed,et al.  Seroprevalence of Antibodies to SARS-CoV-2 in Six Sites in the United States, March 23-May 3, 2020 , 2020, medRxiv.

[11]  A. Goriely,et al.  Global and local mobility as a barometer for COVID-19 dynamics , 2020, Biomechanics and Modeling in Mechanobiology.

[12]  M. Takita,et al.  Regional Difference in Seroprevalence of SARS-CoV-2 in Tokyo: Results from the community point-of-care antibody testing , 2020, medRxiv.

[13]  A. von Eckardstein,et al.  Population-wide evolution of SARS-CoV-2 immunity tracked by a ternary immunoassay , 2020, medRxiv.

[14]  Cesar G Victora,et al.  Remarkable variability in SARS-CoV-2 antibodies across Brazilian regions: nationwide serological household survey in 27 states , 2020, medRxiv.

[15]  David R. Holtgrave,et al.  Cumulative incidence and diagnosis of SARS-CoV-2 infection in New York , 2020, Annals of Epidemiology.

[16]  Gregory M. Goldgof,et al.  SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood from the San Francisco Bay Area , 2020, medRxiv.

[17]  S. Ciesek,et al.  Epidemiological study to detect active SARS-CoV-2 infections and seropositive persons in a selected cohort of employees in the Frankfurt am Main metropolitan area , 2020, medRxiv.

[18]  J. Greenbaum,et al.  Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals , 2020, Cell.

[19]  J. Ioannidis,et al.  The infection fatality rate of COVID-19 inferred from seroprevalence data , 2020, medRxiv.

[20]  R. Krüger,et al.  Prevalence of SARS-CoV-2 infection in the Luxembourgish population: the CON-VINCE study. , 2020, medRxiv.

[21]  S. Bosari,et al.  SARS-CoV-2 seroprevalence trends in healthy blood donors during the COVID-19 Milan outbreak , 2020, medRxiv.

[22]  Daniel Eichner,et al.  Seroprevalence of SARS-CoV-2-Specific Antibodies Among Adults in Los Angeles County, California, on April 10-11, 2020. , 2020, JAMA.

[23]  A. Markotić,et al.  SARS-CoV-2 antibody seroprevalence in industry workers in Split-Dalmatia and Sibenik-Knin County, Croatia , 2020, medRxiv.

[24]  M. Nöthen,et al.  Infection fatality rate of SARS-CoV-2 infection in a German community with a super-spreading event , 2020 .

[25]  M. Wener,et al.  Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence in Boise, Idaho , 2020, Journal of Clinical Microbiology.

[26]  Dusan Petrovic,et al.  Appendix: Seroprevalence of anti-SARS-COV-2 IgG antibodies in a population-based sample from Geneva, Switzerland , 2020 .

[27]  B. Horta,et al.  Population-based surveys of antibodies against SARS-CoV-2 in Southern Brazil , 2020, Nature Medicine.

[28]  T. Morimoto,et al.  Seroprevalence of novel coronavirus disease (COVID-19) in Kobe, Japan , 2020 .

[29]  J. Moon,et al.  COVID-19: PCR screening of asymptomatic health-care workers at London hospital , 2020, The Lancet.

[30]  A. Heidarzadeh,et al.  Seroprevalence of COVID-19 virus infection in Guilan province, Iran , 2020, medRxiv.

[31]  C. Reusken,et al.  Herd immunity is not a realistic exit strategy during a COVID-19 outbreak , 2020 .

[32]  Jens K. Boldsen,et al.  Estimation of SARS-CoV-2 Infection Fatality Rate by Real-time Antibody Screening of Blood Donors , 2020, medRxiv.

[33]  A. Rinaldo,et al.  Spread and dynamics of the COVID-19 epidemic in Italy: Effects of emergency containment measures , 2020, Proceedings of the National Academy of Sciences.

[34]  M. Peirlinck,et al.  Outbreak dynamics of COVID-19 in Europe and the effect of travel restrictions , 2020, medRxiv.

[35]  Xiaodong Wu,et al.  Serological tests facilitate identification of asymptomatic SARS‐CoV‐2 infection in Wuhan, China , 2020, Journal of medical virology.

[36]  P. Klenerman,et al.  Neutralising antibodies to SARS coronavirus 2 in Scottish blood donors - a pilot study of the value of serology to determine population exposure , 2020, medRxiv.

[37]  M. Peirlinck,et al.  Outbreak dynamics of COVID-19 in China and the United States , 2020, Biomechanics and Modeling in Mechanobiology.

[38]  Chonggang Xu,et al.  High Contagiousness and Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2 , 2020, Emerging infectious diseases.

[39]  Johannes Zierenberg,et al.  Inferring change points in the spread of COVID-19 reveals the effectiveness of interventions , 2020, Science.

[40]  S. Butler-Wu,et al.  Community Prevalence of SARS-CoV-2 Among Patients With Influenzalike Illnesses Presenting to a Los Angeles Medical Center in March 2020. , 2020, JAMA.

[41]  S. Bhatt,et al.  Report 13: Estimating the number of infections and the impact of non-pharmaceutical interventions on COVID-19 in 11 European countries , 2020 .

[42]  Sang Woo Park,et al.  Potential roles of social distancing in mitigating the spread of coronavirus disease 2019 (COVID-19) in South Korea , 2020, medRxiv.

[43]  Eric H. Y. Lau,et al.  Temporal dynamics in viral shedding and transmissibility of COVID-19 , 2020, Nature Medicine.

[44]  Ruiyun Li,et al.  Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2) , 2020, Science.

[45]  Sang Woo Park,et al.  The time scale of asymptomatic transmission affects estimates of epidemic potential in the COVID-19 outbreak , 2020, medRxiv.

[46]  Hannah R. Meredith,et al.  The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application , 2020, Annals of Internal Medicine.

[47]  Yaqing Fang,et al.  Transmission dynamics of the COVID‐19 outbreak and effectiveness of government interventions: A data‐driven analysis , 2020, Journal of medical virology.

[48]  R. Redfield,et al.  Covid-19 — Navigating the Uncharted , 2020, The New England journal of medicine.

[49]  Jing Liu,et al.  Asymptomatic cases in a family cluster with SARS-CoV-2 infection , 2020, The Lancet Infectious Diseases.

[50]  E. Dong,et al.  An interactive web-based dashboard to track COVID-19 in real time , 2020, The Lancet Infectious Diseases.

[51]  Jing Zhao,et al.  Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia , 2020, The New England journal of medicine.

[52]  World Health Organization,et al.  Transmission of SARS-CoV-2: implications for infection prevention precautions , 2020 .

[53]  E Kuhl,et al.  Using machine learning to characterize heart failure across the scales , 2019, Biomechanics and Modeling in Mechanobiology.

[54]  F. S. Costabal,et al.  Machine learning in drug development: Characterizing the effect of 30 drugs on the QT interval using Gaussian process regression, sensitivity analysis, and uncertainty quantification. , 2019, Computer methods in applied mechanics and engineering.

[55]  J. Tinsley Oden,et al.  Adaptive multiscale predictive modelling , 2018, Acta Numerica.

[56]  Ivo Babuška,et al.  Predictive Computational Science: Computer Predictions in the Presence of Uncertainty , 2017 .

[57]  J. Oden,et al.  Selection and Validation of Predictive Models of Radiation Effects on Tumor Growth Based on Noninvasive Imaging Data. , 2017, Computer methods in applied mechanics and engineering.

[58]  Tarek I. Zohdi,et al.  An agent-based computational framework for simulation of competing hostile planet-wide populations , 2017 .

[59]  John Salvatier,et al.  Probabilistic programming in Python using PyMC3 , 2016, PeerJ Comput. Sci..

[60]  Andrew Gelman,et al.  The No-U-turn sampler: adaptively setting path lengths in Hamiltonian Monte Carlo , 2011, J. Mach. Learn. Res..

[61]  R. Evans.  European Centre for Disease Prevention and Control. , 2014, Nursing standard (Royal College of Nursing (Great Britain) : 1987).

[62]  Lixing Han,et al.  Implementing the Nelder-Mead simplex algorithm with adaptive parameters , 2010, Computational Optimization and Applications.

[63]  Andrew Gelman,et al.  Data Analysis Using Regression and Multilevel/Hierarchical Models , 2006 .

[64]  C. Fraser,et al.  Factors that make an infectious disease outbreak controllable. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[65]  Herbert W. Hethcote,et al.  The Mathematics of Infectious Diseases , 2000, SIAM Rev..

[66]  Ralf Engbert,et al.  Chance and chaos in population biology—Models of recurrent epidemics and food chain dynamics , 1994 .

[67]  W. O. Kermack,et al.  Contributions to the mathematical theory of epidemics—I , 1991, Bulletin of mathematical biology.

[68]  Jeremy MG Taylor,et al.  Robust Statistical Modeling Using the t Distribution , 1989 .

[69]  I B Schwartz,et al.  Seasonality and period-doubling bifurcations in an epidemic model. , 1984, Journal of theoretical biology.

[70]  W. O. Kermack,et al.  A contribution to the mathematical theory of epidemics , 1927 .